header
1 2 3 4 - Next
 
 
Size and Usage Patterns of Private TB Drug Markets in the High Burden Countries
WILLIAM A. WELLS, COLIN FAN GE, NITIN PATEL, TERESA OH, ELIZABETH GARDINER, MICHAEL E. KIMERLING
PLos One, May 2011 | Volume 6 | Issue 5 | e18964
 
 
Implications of the current tuberculosis treatment landscape for future regimen change
WELLS, W.A.; KONDURI, N.; CHEN, C.; LEE, D.; IGNATIUS, H.R.; GARDINER, E.; SCHWALBE, N.R
The International Journal of Tuberculosis and Lung Disease, Volume 15, Number 6, 745-53.
 
 
Adoption of new health products in low and middle income settings: how product development partnerships can support country decision making
WILLIAM A WELLS AND ALAN BROOKS
Health Research Policy and Systems 2011, 9:15
 
 
Tuberculosis regimen change in high-burden countries
W. A. WELLS, N. KONDURI,C. CHEN, D. LEE, H. R. IGNATIUS, E. GARDINER, N. R. SCHWALBE
INT J TUBERC LUNG DIS 14(12):1538–1547
 
 
Scientific dogmas, paradoxes and mysteries of latent Mycobacterium tuberculosis infection
ALIMUDDIN ZUMLA, RIFAT ATUN, MARKUS MAEURER, PETER MWABA, ZHENKUN MA, JUSTIN O’GRADY, MATTHEW BATES, KEERTAN DHEDA, MICHAEL HOELSCHER AND JOHN GRANGE
Tropical Medicine and International Health.January 2011. volume 16 no 1 pp 79–83 .
 
 
Activity of the Fluoroquinolone DC-159a in the Initial and Continuation Phases of Treatment of Murine Tuberculosis
ZAHOOR AHMAD, AUSTIN MINKOWSKI, CHARLES A. PELOQUIN, KATHY N. WILLIAMS, KHISIMUZI E. MDLULI, JACQUES H. GROSSET, AND ERIC L. NUERMBERGER
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Vol. 55, No. 4, Apr. 2011, p. 1781–1783
 
 
Handbook of anti-tuberculosis agents
GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT
Tuberculosis. 2008. 88: 85-169
 
 
Assessment of global capacity to conduct tuberculosis drug development trials; do we have what it takes?
C, VAN NIEKERK, A. GINSBERG
International Journal of Tuberculosis and Lung Disease. 13(11):1367-1372
 
 
Global tuberculosis drug development pipeline: the need and the reality
ZHENKUN MA, CHRISTIAN LIENHARDT, HELEN MCILLERON, ANDREW J NUNN, XIEXIU WANG
Lancet Series on Tuberculosis, May 19, 2010
 
 
The ethics of non-inferiority trials
NUNN, A.J., ET AL
Lancet. 2008. 371: 895-7
 
1 2 3 4 - Next

Media Support Section
click here

For additional information please email:

newsmedia@tballiance.org

Half-century-old TB drugs get a facelift in new cocktails
12/01/2010
WHO says deadly TB scourge preventable
11/11/2010
David Brennan of AstraZeneca says public sector crucial to drug research
10/11/2010
Regulatory Conference Shows The Way Forward From Lessons Learnt In The Past
8/19/2010
Anti-TB compounds could fight neglected diseases
7/07/2010
click to view all items
  April 2011 Newsletter
  January 2011 Newsletter
  June 2010 Newsletter
  March 2010 Newsletter
  November 2009 Newsletter
  July 2009 Newsletter
  April 2009 Newsletter
  click to view all items